文献速递脑血管病

GLP-1受体激动剂治疗非糖尿病缺血性卒中:系统综述与荟萃分析

GLP-1 Receptor Agonists as Treatment of Nondiabetic Ischemic Stroke: A Systematic Review and Meta-Analysis.
PubMed 文献 · Stroke · 2025-11-20

该系统综述与荟萃分析检索PubMed和Embase,纳入35项研究(31项临床前、4项临床),评估GLP-1受体激动剂在非糖尿病缺血性卒中动物模型和患者中的疗效与安全性。临床前研究显示GLP-1受体激动剂改善功能结局并显著缩小梗死体积,但临床证据有限,近期随机试验未显示对卒中发生率或神经功能恢复有显著效应,且药物安全耐受良好。

要点

  • 临床前动物模型显示GLP-1受体激动剂改善功能结局并缩小梗死体积。
  • 非糖尿病患者中,近期随机试验未显示GLP-1受体激动剂显著改善卒中发生率或神经恢复。
  • GLP-1受体激动剂在急性和慢性场景中均安全且耐受良好。

核心结论

  • 在非糖尿病动物卒中模型中,GLP-1受体激动剂改善功能结局并缩小梗死体积,但转化为临床获益仍是关键挑战。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed和Embase(2024年6月20日,2025年3月6日重复),纳入35项研究(31项临床前、4项临床),应用9种GLP-1疗法。

主要发现

  • 临床前动物卒中模型中,GLP-1受体激动剂较载体(安慰剂)改善功能结局并显著缩小梗死体积。
  • 提出机制包括减少氧化应激、缺氧触发的细胞死亡和急性缺血性卒中后炎症反应。
  • 近期随机试验未显示非糖尿病患者接受GLP-1受体激动剂后卒中发生率或神经功能恢复有显著效应。
  • GLP-1受体激动剂在急性和慢性场景中均安全且耐受良好。

临床怎么用

  • 目前临床证据有限,不推荐将GLP-1受体激动剂用于非糖尿病缺血性卒中的神经功能恢复。

局限性

  • 临床证据有限,临床前有前景的发现向临床获益转化仍存在挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Reperfusion therapies for ischemic stroke are a cornerstone of acute treatment, though only available for a subset of patients due to a narrow time window. Other supplementary treatment is warranted, as only half of the patients reach functional independence. GLP-1 RA (glucagon-like peptide-1 receptor agonists) are associated with decreased cardiovascular disease, mainly driven by reduced stroke risk, and have gained interest as therapeutic agents for stroke recovery in experimental stroke models. This review aims to evaluate the current data on the effect and safety of GLP-1 RA in nondiabetic patients with ischemic stroke and in animal models of cerebral ischemia. We will describe its potential neuroprotective mechanisms. METHODS: On June 20, 2024, keyword-based literature searches were conducted in PubMed and Embase and repeated on March 6, 2025. Records evaluating GLP-1-based therapies in animals and patients with ischemic stroke who did not have diabetes were included. RESULTS: In total, 35 studies, 31 preclinical and 4 clinical, applying 9 different GLP-1 therapies were reviewed. GLP-1 RA improved functional outcome and induced a marked infarct volume reduction compared with vehicle (placebo) in preclinical animal stroke models. The proposed mechanisms include reduced oxidative stress, hypoxia-triggered cell death, and inflammatory response following acute ischemic stroke. Despite these neuroprotective effects observed in stroke models, evidence for improved clinical outcomes in humans remains limited. Recent randomized trials have not shown a significant effect on stroke incidence or neurological recovery in patients without diabetes who are treated with GLP-1 RA. GLP-1 RA appears safe and well-tolerated in both acute and chronic settings. CONCLUSIONS: GLP-1 RA improves functional outcome and reduces infarct volume in preclinical animal stroke models without diabetes. Translating these promising preclinical findings into clinical benefits remains a key challenge and a critical opportunity for future research.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Michaelsen MK, Drasbek KR, Valentin JB, et al. GLP-1 Receptor Agonists as Treatment of Nondiabetic Ischemic Stroke: A Systematic Review and Meta-Analysis. Stroke. 2025. PMID: 41263069. doi:10.1161/STROKEAHA.125.053075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。